Pritelivir Shows Promise for Refractory HSV in Immunocompromised Patients

A new antiviral drug, pritelivir, is showing significant promise in treating herpes simplex virus (HSV) infections in individuals with weakened immune systems. Results from a phase 3 clinical trial demonstrate superior efficacy in healing lesions compared to standard treatments, offering a potential breakthrough for a population with limited options.

Pritelivir’s Impact on Immunocompromised Patients

The study, presented at the Conference on Retroviruses and Opportunistic Infections in February 2026, involved 101 immunocompromised adults with HSV infections that were resistant or unresponsive to other therapies. Participants were randomly assigned to receive either pritelivir, developed by Aicuris, or treatment chosen by their physician – including intravenous foscarnet, intravenous/topical cidofovir, or topical imiquimod. The findings revealed that 62.7% of patients treated with pritelivir experienced complete lesion healing, a substantial improvement over the 34% healing rate observed in the control group. This translates to a treatment difference of 28.7 percentage points (95% CI, 8%-47.1%).

This is particularly encouraging for individuals living with HIV, transplant recipients, and others whose immune systems are compromised, leaving them vulnerable to severe and prolonged HSV outbreaks. As Dr. Jean-Michel Molina, the French physician and researcher who presented the study, explained, there is a “high medical need for effective and well-tolerated treatment options” for this patient group. Healio reports Molina describing the findings as “highly significant.”

How Pritelivir Works: A Novel Approach

Unlike existing antiviral medications like acyclovir, which require activation by viral enzymes, pritelivir targets the viral helicase-primase complex – a crucial component for viral replication. This mechanism allows pritelivir to be effective even in cells that haven’t yet been infected, potentially preventing the spread of the virus. Molina noted that pritelivir demonstrated both lesion healing and a reduction in viral shedding.

Study Design and Considerations

The randomized, controlled, open-label study included participants with a mean age of 52.6 years, with slightly more than half being male (52.5%). Participants received a 400 mg loading dose of pritelivir followed by 28 days of a 100 mg daily maintenance dose. The primary endpoint of the study was complete lesion healing within 28 days, while safety and tolerability were assessed as secondary endpoints.

It’s important to note that this was an open-label study, meaning both researchers and participants were aware of the treatment assignments. This design can introduce bias, as expectations might influence outcomes. Further research, including double-blinded studies, will be crucial to confirm these findings and minimize potential biases. The study’s findings were initially published as Abstract 196 at the Conference on Retroviruses and Opportunistic Infections.

Breakthrough Therapy Designation and Regulatory Pathway

The U.S. Food and Drug Administration (FDA) has granted pritelivir a Breakthrough Therapy designation, a program designed to expedite the development and review of drugs for serious conditions. This designation is based on promising early clinical trial results. Aicuris anticipates submitting an application for FDA approval in the first quarter of 2026. FedEx has issued a service disruption alert for March 1, 2026, which may impact the delivery of medications, though this is unrelated to the drug itself.

The Global Burden of Herpes Simplex Virus

The need for new HSV treatments is underscored by the global prevalence of the virus. According to 2024 data from the World Health Organization (WHO), an estimated 42 million new genital herpes infections occur annually among individuals aged 15 to 49 years – roughly one new infection every second. The WHO provides comprehensive information on STIs, including HSV.

A Long-Awaited Innovation

Dr. Cynthia Wat, Chief Medical Officer at Aicuris, highlighted the lack of innovation in HSV treatment over the past two decades. “For more than 2 decades, there has been no innovation in antiviral medicines for HSV, leaving clinicians with limited treatment options for patients who do not respond to existing antivirals,” Wat stated in an Aicuris press release. Molina echoed this sentiment, suggesting that pritelivir could be “the first oral antiviral against herpes infection since the discovery of acyclovir in the 1980s.”

What’s Next for Pritelivir?

The FDA’s review of the application for pritelivir will be a critical next step. If approved, the drug could significantly improve the quality of life for immunocompromised individuals struggling with refractory HSV infections. Ongoing surveillance will be essential to monitor the drug’s long-term safety and effectiveness in real-world settings. Further research may similarly explore the potential of pritelivir in other populations and for different types of HSV infections.

Individuals concerned about HSV infections should consult with a qualified healthcare professional for diagnosis and treatment options. It’s also important to stay informed about the latest public health updates and guidance from organizations like the CDC and WHO. CISA has issued alerts regarding cybersecurity vulnerabilities, which is a reminder to protect personal health information when accessing online resources.

For more information: Dr. Jean-Michel Molina can be reached at [email protected].